Hansa Biopharma AB (OSTO:HNSA) Buildings And Improvements : kr0.0 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Hansa Biopharma AB Buildings And Improvements?

Hansa Biopharma AB's quarterly buildings and improvements increased from Sep. 2023 (kr0.0 Mil) to Dec. 2023 (kr20.6 Mil) but then declined from Dec. 2023 (kr20.6 Mil) to Mar. 2024 (kr0.0 Mil).

Hansa Biopharma AB's annual buildings and improvements declined from Dec. 2021 (kr34.4 Mil) to Dec. 2022 (kr27.3 Mil) and declined from Dec. 2022 (kr27.3 Mil) to Dec. 2023 (kr20.6 Mil).

Hansa Biopharma AB Buildings And Improvements Historical Data

The historical data trend for Hansa Biopharma AB's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansa Biopharma AB Buildings And Improvements Chart

Hansa Biopharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

8.12

3.57

34.45

27.25

20.58

Hansa Biopharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	20.58	-

Hansa Biopharma AB Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Hansa Biopharma AB (OSTO:HNSA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hansa Biopharma AB (OSTO:HNSA) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

HNSBF:USA 0RC7:UK 24H:Germany

Address

Scheelevagen 22, Lund, SWE, 223 63

Website

https://www.hansabiopharma.com

Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.

Hansa Biopharma AB (OSTO:HNSA) Headlines

No Headlines